ÂÜÀòÂÒÂ×

Trevor A. Crowell

Director, Clinical Research Directorate at MHRP

Dr. Crowell is the Director of the Clinical Research Directorate at MHRP, where he oversees cohorts and other epidemiologic studies of HIV, sexually transmitted infections, and other infectious disease threats to global public health and U.S. military force readiness.

Dr. Crowell is a physician specialist in infectious diseases who received his M.D. from the University of Southern California Keck School of Medicine and his Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. He completed his residency in internal medicine and international health at University Hospitals Case Medical Center and his fellowship in infectious diseases at the Johns Hopkins University School of Medicine.

Dr. Crowell is an associate professor in the Division of Infectious Diseases at the Uniformed Services University and has an adjunct appointment at Johns Hopkins University, where he provides inpatient consultative clinical care. He is a Deputy Editor for the Journal of the International AIDS Society and serves on the editorial boards of AIDS and AIDS Research and Therapy. He is an active investigator with the NIH-sponsored AIDS Clinical Trials Group (ACTG), having served as an elected member of the Reservoirs Remission and Cure Transformative Science Group and on the leadership teams for multinational studies of acute HIV infection and the use of broadly-neutralizing antibodies for HIV therapy. He is a past recipient of the ACTG John Carey Young Investigator Award.

Dr. Crowell has published extensively on clinical outcomes among persons living with or at risk for HIV, with a focus on U.S. military service members, sexual and gender minority populations, elite controllers, and individuals diagnosed during acute HIV infection. His current research also includes clinical trials of preventive vaccine candidates for HIV and other infectious diseases as well as novel interventions to achieve durable suppression of HIV without daily antiretroviral therapy.